Private Market View

BioScene Pharma

Changzhou, China · Founded 2020 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Changzhou Honghui Holding Group, Ruitai Venture Capital.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for BioScene Pharma
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for BioScene Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About BioScene Pharma

Developer of pharmaceutical solutions designed for improved new drugs and high-end generic medicines. The company provides advanced drug delivery systems and AI-powered research services, enabling global pharmaceutical industry users with innovative R&D and technology transfer solutions.

Sector
Healthcare
HQ
Changzhou, China
Founded
2020
Ownership
Privately Held (backing)
PA Mark — not yet priced

BioScene Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in BioScene Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on BioScene Pharma in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.